712 related articles for article (PubMed ID: 30094732)
21. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
23. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a single institute].
Osawa H; Goto H; Myojo T
Gan To Kagaku Ryoho; 2013 May; 40(5):617-21. PubMed ID: 23863585
[TBL] [Abstract][Full Text] [Related]
25. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
26. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
[TBL] [Abstract][Full Text] [Related]
27. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
28. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
Uchida M; Nakamura T; Makihara Y; Suetsugu K; Ikesue H; Mori Y; Kato K; Shiratsuchi M; Hosohata K; Miyamoto T; Akashi K
Pharmazie; 2018 May; 73(5):304-308. PubMed ID: 29724299
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
30. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
[TBL] [Abstract][Full Text] [Related]
32. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Hatoum HT; Lin SJ; Buchner D; Cox D
Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
[TBL] [Abstract][Full Text] [Related]
33. Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
Yokoyama S; Tamaru S; Tamaki S; Nakanishi D; Mori A; Yamakawa T; Ao T; Sakata Y; Mizuno T; Iwamoto T; Watanabe K; Simomura M; Kawakami K; Konishi N; Kageyama S; Ohtani S; Yamada T; Ban S; Ooi K
Clin Breast Cancer; 2018 Apr; 18(2):e157-e165. PubMed ID: 28735677
[TBL] [Abstract][Full Text] [Related]
34. 5HT
Hayashi T; Shimokawa M; Matsuo K; Nishimura J; Iihara H; Nakano T; Egawa T
Cancer Sci; 2021 Feb; 112(2):744-750. PubMed ID: 33274555
[TBL] [Abstract][Full Text] [Related]
35. Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Uchida M; Mori Y; Nakamura T; Kato K; Kamezaki K; Takenaka K; Shiratsuchi M; Kadoyama K; Miyamoto T; Akashi K
Biol Pharm Bull; 2017; 40(9):1499-1505. PubMed ID: 28867732
[TBL] [Abstract][Full Text] [Related]
36. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
[TBL] [Abstract][Full Text] [Related]
37. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population.
Tian W; Wang Z; Zhou J; Zhang S; Wang J; Chen Q; Huang C; Pan L; Zhang L; Huang J; Shen H; Lin T
Med Oncol; 2011 Mar; 28(1):71-8. PubMed ID: 20049561
[TBL] [Abstract][Full Text] [Related]
38. Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?
Keat CH; Phua G; Abdul Kassim MS; Poh WK; Sriraman M
Asian Pac J Cancer Prev; 2013; 14(1):469-73. PubMed ID: 23534775
[TBL] [Abstract][Full Text] [Related]
39. Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Vacirca J; Caruana D; Calcanes G; Mosier M; Boccia R; McBride A
Future Oncol; 2018 Jun; 14(14):1387-1396. PubMed ID: 29421926
[TBL] [Abstract][Full Text] [Related]
40. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Navari RM; Nelson WW; Shoaib S; Singh R; Zhang W; Bailey WL
Adv Ther; 2023 Jul; 40(7):3217-3226. PubMed ID: 37245189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]